TABLE OF CONTENT
CHAPTER 1. REPORT PROLOGUE
CHAPTER 2. MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
CHAPTER 3. RESEARCH METHODOLOGY
3.1 INTRODUCTION
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
CHAPTER 4. MARKET DYNAMICS
4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
4.4 CHALLENGES
4.5 MACROECONOMIC INDICATORS
4.6 TECHNOLOGY TRENDS & ASSESSMENT
CHAPTER 5. MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY
5.2 VALUE CHAIN ANALYSIS
5.3 INVESTMENT FEASIBILITY ANALYSIS
5.4 PRICING ANALYSIS
CHAPTER 6. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS
6.1 INTRODUCTION
6.2 PELVIC EXAMINATION
6.3 TRANSVAGINAL ULTRASOUND
6.4 BLOOD TESTS
6.4.1 HORMONE LEVELS
6.4.2 GLUCOSE TOLERANCE
6.4.3 CHOLESTEROL AND TRIGLYCERIDE LEVELS
7. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT
7.1 INTRODUCTION
7.2 ORAL CONTRACEPTIVES
7.3 ANTIANDROGENS
7.4 INSULIN SENSITIZING AGENT
7.5 ANTIDEPRESSANT
7.6 ANTI-OBESITY
7.7 SURGERY
7.7.1 OVARIAN WEDGE RESECTION
7.7.2 LAPAROSCOPIC OVARIAN DRILLING
CHAPTER 8. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER
8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 AMBULATORY SURGICAL CENTERS
8.4 DIAGNOSTIC CENTERS
8.5 GYNECOLOGY CENTERS
8.6 FEMINIST HEALTH CENTERS
CHAPTER 9. GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY REGION
9.1 INTRODUCTION
9.2 AMERICA
9.2.1 NORTH AMERICA
9.2.1.1 US
9.2.1.2 CANADA
9.2.2 SOUTH AMERICA
9.3 EUROPE
9.3.1 WESTERN EUROPE
9.3.1.1 GERMANY
9.3.1.2 FRANCE
9.3.1.3 ITALY
9.3.1.4 SPAIN
9.3.1.5 UK
9.3.1.6 REST OF WESTERN EUROPE
9.3.2 EASTERN EUROPE
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 REPUBLIC OF KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 UNITED ARAB EMIRATES
9.5.2 SAUDI ARABIA
9.5.3 OMAN
9.5.4 KUWAIT
9.5.5 QATAR
9.5.6 REST OF THE MIDDLE EAST & AFRICA
CHAPTER 10. COMPANY LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS
10.3 KEY DEVELOPMENT & STRATEGIES
10.3.1 KEY DEVELOPMENTS
CHAPTER 11 COMPANY PROFILES
11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 TYPE OVERVIEW
11.1.3 FINANCIALS
11.2.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.2 ASTRAZENECA PLC
11.2.1 COMPANY OVERVIEW
11.2.2 TYPE OVERVIEW
11.2.3 FINANCIAL OVERVIEW
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.3 ABBOTT
11.3.1 COMPANY OVERVIEW
11.3.2 TYPE OVERVIEW
11.3.3 FINANCIAL OVERVIEW
11.3.4 KEY DEVELOPMENT
11.3.5 SWOT ANALYSIS
11.4 BIOCINESE
11.4.1 COMPANY OVERVIEW
11.4.2 TYPE/BUSINESS SEGMENT OVERVIEW
11.4.3 FINANCIAL OVERVIEW
11.4.4 KEY DEVELOPMENT
11.4.5 SWOT ANALYSIS
11.5 CATALYSIS
11.5.1 COMPANY OVERVIEW
11.5.2 TYPE OVERVIEW
11.5.3 FINANCIAL OVERVIEW
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.6 CRINETICS PHARMACEUTICALS, INC
11.6.1 COMPANY OVERVIEW
11.6.2 TYPE OVERVIEW
11.6.3 FINANCIAL OVERVIEW
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.7 SANOFI.
11.7.1 OVERVIEW
11.7.2 TYPE OVERVIEW
11.7.3 FINANCIALS
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.8 EUGONIA
11.8.1 OVERVIEW
11.8.2 TYPE OVERVIEW
11.8.3 FINANCIALS
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.9 EFFRX, INC.
11.9.1 OVERVIEW
11.9.2 TYPE OVERVIEW
11.9.3 FINANCIALS
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.10 FERRING PHARMACEUTICALS, INC
11.10.1 OVERVIEW
11.10.2 TYPE OVERVIEW
11.10.3 FINANCIALS
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.11 MERCK KGAA
11.11.1 OVERVIEW
11.11.2 TYPE OVERVIEW
11.11.3 FINANCIALS
11.11.4 KEY DEVELOPMENTS
11.11.5 SWOT ANALYSIS
11.12 BRISTOL-MYER SQUIBB COMPANY
11.12.1 OVERVIEW
11.12.2 TYPE OVERVIEW
11.12.3 FINANCIALS
11.12.4 KEY DEVELOPMENTS
11.12.5 SWOT ANALYSIS
11.13 NEUROCRINE BIOSCIENCES
11.13.1 OVERVIEW
11.13.2 TYPE OVERVIEW
11.13.3 FINANCIALS
11.13.4 KEY DEVELOPMENTS
11.13.5 SWOT ANALYSIS
11.14 RELIANCE LIFE SCIENCES PVT. LTD
11.14.1 OVERVIEW
11.14.2 TYPE OVERVIEW
11.14.3 FINANCIALS
11.14.4 KEY DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.15 PFIZER, INC
11.14.1 OVERVIEW
11.14.2 TYPE OVERVIEW
11.14.3 FINANCIALS
11.14.4 KEY DEVELOPMENTS
11.14.5 SWOT ANALYSIS
11.15 OTHERS
CHAPTER 12 APPENDIX
LIST OF TABLES
TABLE 1 POLYCYSTIC OVARIAN SYNDROME MARKET INDUSTRY SYNOPSIS, 2023–2030
TABLE 2 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET ESTIMATES & FORECAST, 2023–2030, (USD MILLION)
TABLE 3 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY REGION, 2023–2030, (USD MILLION)
TABLE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 7 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 8 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 9 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 10 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 11 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 12 US POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 13 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 14 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 15 CANADA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 16 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 17 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 18 SOUTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 19 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 20 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 21 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 22 WESTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 23 WESTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 24 WESTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 25 EASTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE26 EASTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 27 EASTERN EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 28 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 29 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 30 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY DIAGNOSIS, 2023–2030, (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY TREATMENT, 2023–2030, (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME MARKET, BY END-USER, 2023–2030, (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 SEGMENTATION FOR GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET
FIGURE 3 MARKET DYNAMICS FOR GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET
FIGURE 4 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY DIAGNOSIS 2023
FIGURE 5 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY TREATMENT 2023
FIGURE 6 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY END-USER, 2023
FIGURE 7 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY REGION, 2023
FIGURE 8 NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2023
FIGURE 9 EUROPE POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2023
FIGURE 10 ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2023
FIGURE 11 MIDDLE EAST & AFRICA POLYCYSTIC OVARIAN SYNDROME MARKET SHARE, BY COUNTRY, 2023
FIGURE 12 GLOBAL POLYCYSTIC OVARIAN SYNDROME MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 BAYER AG: KEY FINANCIALS
FIGURE 14 BAYER AG: SEGMENTAL REVENUE
FIGURE 15 BAYER AG: GEOGRAPHICAL REVENUE
FIGURE 16 ASTRAZENECA PLC: KEY FINANCIALS
FIGURE 17 ASTRAZENECA PLC: SEGMENTAL REVENUE
FIGURE 18 ASTRAZENECA PLC: GEOGRAPHICAL REVENUE
FIGURE 19 ABBOTT: KEY FINANCIALS
FIGURE 20 ABBOTT: SEGMENTAL REVENUE
FIGURE 21 ABBOTT: GEOGRAPHICAL REVENUE
FIGURE 22 BIOCINESE: KEY FINANCIALS
FIGURE 23 BIOCINESE: SEGMENTAL REVENUE
FIGURE 24 BIOCINESE: GEOGRAPHICAL REVENUE
FIGURE 25 CRINETICS PHARMACEUTICALS, INC: KEY FINANCIALS
FIGURE 26 CRINETICS PHARMACEUTICALS, INC: SEGMENTAL REVENUE
FIGURE 27 CRINETICS PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE
FIGURE 28 CATALYSIS: KEY FINANCIALS
FIGURE 29 CATALYSIS: SEGMENTAL REVENUE
FIGURE 30 CATALYSIS: GEOGRAPHICAL REVENUE
FIGURE 31 SANOFI: KEY FINANCIALS
FIGURE 32 SANOFI: SEGMENTAL REVENUE
FIGURE 33 SANOFI: GEOGRAPHICAL REVENUE
FIGURE 34 EUGONIA: KEY FINANCIALS
FIGURE 35 EUGONIA: SEGMENTAL REVENUE
FIGURE 36 EUGONIA: GEOGRAPHICAL REVENUE
FIGURE 37 EFFRX, INC.: KEY FINANCIALS
FIGURE 38 EFFRX, INC.: SEGMENTAL REVENUE
FIGURE 39 EFFRX, INC.: GEOGRAPHICAL REVENUE
FIGURE 40 FERRING PHARMACEUTICALS, INC: KEY FINANCIALS
FIGURE 41 FERRING PHARMACEUTICALS, INC: SEGMENTAL REVENUE
FIGURE 42 FERRING PHARMACEUTICALS, INC: GEOGRAPHICAL REVENUE
FIGURE 46 BRISTOL-MYER SQUIBB COMPANY: KEY FINANCIALS
FIGURE 47 BRISTOL-MYER SQUIBB COMPANY: SEGMENTAL REVENUE
FIGURE 48 BRISTOL-MYER SQUIBB COMPANY: GEOGRAPHICAL REVENUE
FIGURE 49 NEUROCRINE BIOSCIENCES: KEY FINANCIALS
FIGURE 50 NEUROCRINE BIOSCIENCES: SEGMENTAL REVENUE
FIGURE 51 NEUROCRINE BIOSCIENCES: GEOGRAPHICAL REVENUE
FIGURE 52 C.R. BARD: KEY FINANCIALS
FIGURE 53 C.R. BARD: SEGMENTAL REVENUE
FIGURE 54 C.R. BARD: GEOGRAPHICAL REVENUE
FIGURE 55 RELIANCE LIFE SCIENCES PVT. LTD: KEY FINANCIALS
FIGURE 56 RELIANCE LIFE SCIENCES PVT. LTD: SEGMENTAL REVENUE
FIGURE 57 RELIANCE LIFE SCIENCES PVT. LTD: GEOGRAPHICAL REVENUE
FIGURE 58 PFIZER, INC: KEY FINANCIALS
FIGURE 59 PFIZER, INC: SEGMENTAL REVENUE
FIGURE 60 PFIZER, INC: GEOGRAPHICAL REVENUE
